vs

Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Turtle Beach Corp (TBCH). Click either name above to swap in a different company.

Turtle Beach Corp is the larger business by last-quarter revenue ($95.1M vs $57.3M, roughly 1.7× RHYTHM PHARMACEUTICALS, INC.). Turtle Beach Corp runs the higher net margin — 18.5% vs -83.0%, a 101.5% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -34.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 30.5%).

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

The Turtle Beach Corporation is an American gaming accessory manufacturer based in San Diego, California. The company has roots dating back to the 1970s where it developed sound cards, MIDI synthesizers, and various audio software packages and network audio devices. The company began making gaming headsets in 2005.

RYTM vs TBCH — Head-to-Head

Bigger by revenue
TBCH
TBCH
1.7× larger
TBCH
$95.1M
$57.3M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+71.8% gap
RYTM
36.9%
-34.9%
TBCH
Higher net margin
TBCH
TBCH
101.5% more per $
TBCH
18.5%
-83.0%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
30.5%
TBCH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RYTM
RYTM
TBCH
TBCH
Revenue
$57.3M
$95.1M
Net Profit
$-47.5M
$17.6M
Gross Margin
91.6%
50.0%
Operating Margin
-82.2%
22.0%
Net Margin
-83.0%
18.5%
Revenue YoY
36.9%
-34.9%
Net Profit YoY
-9.6%
-12.6%
EPS (diluted)
$-0.73
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RYTM
RYTM
TBCH
TBCH
Q4 25
$57.3M
$95.1M
Q3 25
$51.3M
$80.5M
Q2 25
$48.5M
$80.5M
Q1 25
$32.7M
$63.9M
Q4 24
$41.8M
$146.1M
Q3 24
$33.3M
$94.4M
Q2 24
$29.1M
$76.5M
Q1 24
$26.0M
$55.8M
Net Profit
RYTM
RYTM
TBCH
TBCH
Q4 25
$-47.5M
$17.6M
Q3 25
$-52.9M
$1.7M
Q2 25
$-46.6M
$-2.9M
Q1 25
$-49.5M
$-664.0K
Q4 24
$-43.3M
$20.1M
Q3 24
$-43.6M
$3.4M
Q2 24
$-32.3M
$-7.5M
Q1 24
$-141.4M
$155.0K
Gross Margin
RYTM
RYTM
TBCH
TBCH
Q4 25
91.6%
50.0%
Q3 25
89.3%
37.4%
Q2 25
88.6%
22.7%
Q1 25
88.8%
36.6%
Q4 24
90.9%
37.0%
Q3 24
88.5%
36.2%
Q2 24
89.9%
30.2%
Q1 24
89.2%
31.8%
Operating Margin
RYTM
RYTM
TBCH
TBCH
Q4 25
-82.2%
22.0%
Q3 25
-102.6%
6.7%
Q2 25
-93.4%
-0.4%
Q1 25
-143.7%
2.4%
Q4 24
-98.6%
16.0%
Q3 24
-132.0%
6.8%
Q2 24
-139.2%
-5.4%
Q1 24
-538.7%
-10.2%
Net Margin
RYTM
RYTM
TBCH
TBCH
Q4 25
-83.0%
18.5%
Q3 25
-103.1%
2.1%
Q2 25
-96.1%
-3.6%
Q1 25
-151.4%
-1.0%
Q4 24
-103.6%
13.8%
Q3 24
-131.2%
3.6%
Q2 24
-110.9%
-9.8%
Q1 24
-544.4%
0.3%
EPS (diluted)
RYTM
RYTM
TBCH
TBCH
Q4 25
$-0.73
$0.86
Q3 25
$-0.82
$0.08
Q2 25
$-0.75
$-0.14
Q1 25
$-0.81
$-0.03
Q4 24
$-0.71
$0.96
Q3 24
$-0.73
$0.16
Q2 24
$-0.55
$-0.35
Q1 24
$-2.35
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RYTM
RYTM
TBCH
TBCH
Cash + ST InvestmentsLiquidity on hand
$388.9M
$17.0M
Total DebtLower is stronger
$55.7M
Stockholders' EquityBook value
$139.1M
$128.5M
Total Assets
$480.2M
$269.1M
Debt / EquityLower = less leverage
0.43×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RYTM
RYTM
TBCH
TBCH
Q4 25
$388.9M
$17.0M
Q3 25
$416.1M
$12.3M
Q2 25
$291.0M
$11.7M
Q1 25
$314.5M
$11.7M
Q4 24
$320.6M
$13.0M
Q3 24
$298.4M
$13.8M
Q2 24
$319.1M
$12.5M
Q1 24
$201.2M
$17.8M
Total Debt
RYTM
RYTM
TBCH
TBCH
Q4 25
$55.7M
Q3 25
$57.9M
Q2 25
$43.3M
Q1 25
$48.6M
Q4 24
$49.0M
Q3 24
$49.3M
Q2 24
$49.6M
Q1 24
$49.9M
Stockholders' Equity
RYTM
RYTM
TBCH
TBCH
Q4 25
$139.1M
$128.5M
Q3 25
$148.8M
$110.7M
Q2 25
$-11.9M
$116.8M
Q1 25
$18.9M
$120.9M
Q4 24
$21.7M
$120.6M
Q3 24
$11.2M
$101.8M
Q2 24
$39.3M
$105.3M
Q1 24
$61.6M
$125.2M
Total Assets
RYTM
RYTM
TBCH
TBCH
Q4 25
$480.2M
$269.1M
Q3 25
$506.9M
$278.2M
Q2 25
$372.7M
$240.2M
Q1 25
$386.7M
$247.0M
Q4 24
$392.3M
$298.9M
Q3 24
$363.6M
$313.2M
Q2 24
$381.8M
$264.4M
Q1 24
$258.7M
$258.4M
Debt / Equity
RYTM
RYTM
TBCH
TBCH
Q4 25
0.43×
Q3 25
0.52×
Q2 25
0.37×
Q1 25
0.40×
Q4 24
0.41×
Q3 24
0.48×
Q2 24
0.47×
Q1 24
0.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RYTM
RYTM
TBCH
TBCH
Operating Cash FlowLast quarter
$-25.4M
$13.3M
Free Cash FlowOCF − Capex
$13.1M
FCF MarginFCF / Revenue
13.8%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
0.76×
TTM Free Cash FlowTrailing 4 quarters
$34.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RYTM
RYTM
TBCH
TBCH
Q4 25
$-25.4M
$13.3M
Q3 25
$-26.6M
$-15.2M
Q2 25
$-23.3M
$-3.1M
Q1 25
$-40.4M
$40.5M
Q4 24
$-18.8M
$14.3M
Q3 24
$-25.2M
$-23.2M
Q2 24
$-29.1M
$-12.6M
Q1 24
$-40.7M
$27.3M
Free Cash Flow
RYTM
RYTM
TBCH
TBCH
Q4 25
$13.1M
Q3 25
$-15.9M
Q2 25
$-3.5M
Q1 25
$40.3M
Q4 24
$12.8M
Q3 24
$-24.6M
Q2 24
$-13.9M
Q1 24
$26.5M
FCF Margin
RYTM
RYTM
TBCH
TBCH
Q4 25
13.8%
Q3 25
-19.7%
Q2 25
-4.3%
Q1 25
63.0%
Q4 24
8.8%
Q3 24
-26.1%
Q2 24
-18.1%
Q1 24
47.5%
Capex Intensity
RYTM
RYTM
TBCH
TBCH
Q4 25
0.3%
Q3 25
0.8%
Q2 25
0.4%
Q1 25
0.3%
Q4 24
1.0%
Q3 24
1.5%
Q2 24
1.6%
Q1 24
1.3%
Cash Conversion
RYTM
RYTM
TBCH
TBCH
Q4 25
0.76×
Q3 25
-8.84×
Q2 25
Q1 25
Q4 24
0.71×
Q3 24
-6.79×
Q2 24
Q1 24
175.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RYTM
RYTM

Segment breakdown not available.

TBCH
TBCH

Europe And Middle East$71.0M75%
Asia Pacific$13.3M14%
Other$10.8M11%

Related Comparisons